NCT04847206View on ClinicalTrials.gov

Effects of MDMA-like Substances in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions
Healthy
Interventions
DRUG

3,4-methylenedioxymethamphetamine

A moderate dose of 100 mg MDMA will be administered.

DRUG

3,4-methylenedioxyamphetamine

A moderate dose of 93.9 mg MDA will be administered.

DRUG

lysine-3,4-methylenedioxymethamphetamine

A moderate dose of 171.7 mg lysine-MDMA will be administered.

DRUG

lysine-3,4-methylenedioxyamphetamine

A moderate dose of 165.6 mg lysine-MDA will be administered.

OTHER

Placebo

Placebo (Mannitol)

Trial Locations (1)

4056

University Hospital Basel, Clinical Trial Unit, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04847206 - Effects of MDMA-like Substances in Healthy Subjects | Biotech Hunter | Biotech Hunter